Multi-organ protection as a result of angiotensin-converting enzyme inhibition with benazepril Review article

Abstract

Angiotensin-converting enzyme inhibitor benazepril is a long acting drug with high affinity for tissue renin-angiotensin system. Benazepril has been extensively studied in randomized clinical trials involving different populations of patients. The clinical efficacy was confirmed in patients with hypertension, as well as in populations with very high cardiovascular risk such as patients with diabetes, coronary artery disease or advanced chronic kidney disease. The paper presents studies which showed that treatment with benazepril reduces cardiovascular risk and slows progression of renal failure. It seems that cardio- and nephroprotective properties of the drug are not entirely related to blood pressure.